*Read Disclaimer Sponsored Content
{{current_date_full}} | Unsubscribe
Hello!
New Alert: Healthcare Triangle, Inc. (Nasdaq: HCTI)
HCTI is our brand new NASDAQ breakout alert.
The company is positioned in one of the hottest sectors today – AI.
With big recent acquisition news…
HCTI has a history of experiencing significant volatility in a very short period of time.
In addition, HCTI has been building a base for weeks now, increasing the likelihood of a breakout opportunity.
Earlier this month, HCTI rallied as high as 3.40…
That’s over 29% from yesterday’s close.
Furthermore, HCTI is right at its 50 day moving average.
Historically, after such a prolonged consolidation that could become a launchpad for a rally higher.
Plus, HCTI has a RSI of 46.
This creates the opportunity for increased gains.
HCTI is a NASDAQ listed “leader in digital transformation solutions for healthcare and life sciences”.
HCTI “based in Pleasanton, California, reinforces healthcare progress through breakthrough technology and extensive industry knowledge and expertise”.
The company supports “healthcare organizations including hospitals and health systems, payers, and pharma/life sciences organizations in their effort to improve health outcomes through better utilization of the data and information technologies that they rely on”.
HCTI “achieves HITRUST Certification for Cloud and Data Platform (CaDP), marketed as CloudEz™ and DataEz™. HITRUST Risk-based, 2-year (r2) Certified status demonstrates to our clients the highest standards for data protection and information security”.
HCTI “enables the adoption of new technologies, data enlightenment, business agility, and response to immediate business needs and competitive threats”.
The highly regulated healthcare and life sciences industries rely on HCTI for “expertise in digital transformation encompassing the cloud, security and compliance, data lifecycle management, healthcare interoperability, and clinical & business performance optimization”.
Earlier this month, the company announced:
“Healthcare Triangle Subsidiary QuantumNexis Reports $20M in Consumption-Based Revenue Processed on Ezovion Platform, Forecasts $37M Amid Rapid Growth”
Here are some of the highlights:
“QuantumNexis's Ezovion Electronic Medical Record (EMR) platform has processed over $20 million in revenue generated by healthcare providers who rely on the platform to digitize and manage their operations.”
“This milestone underscores Ezovion's expanding role as the digital infrastructure powering hospitals, clinics, and specialty care providers across multiple markets, enabling seamless digitization, streamlined workflows, and improved patient outcomes.”
“As QuantumNexis accelerates its global expansion into India, Bangladesh, Saudi Arabia, and Malaysia, the total revenue processed through the platform by end users is projected to surge from $20 million to $37 million over the next six months. This growth reflects both rapid adoption by new customers and deeper engagement by existing healthcare providers who are expanding their digital footprints.”
Strategic Impact for Shareholders
“The QuantumNexis milestone and payment gateway launch create multiple value growth drivers for HCTI”:
“$20M+ in end-user revenue already processed through the Ezovion platform, demonstrating strong market traction and platform adoption.”
“Projected growth to $37M in end-user revenue within six months, driven by aggressive international expansion and deeping customer engagement with existing customers.”
“Launch of an integrated payment gateway to directly monetize transaction flows, transforming platform activity into predictable recurring revenue for HCTI.”
“Strategic positioning as a hybrid SaaS + fintech company, creating a differentiated investment thesis that appeals to both healthcare technology and fintech-focused institutional investors.”
“Initial payment gateway deployments planned for late 2025, with comprehensive global scaling throughout 2026.”
David Ayanoglou, Chief Financial Officer of Healthcare Triangle Inc, concluded,
"The rapid increase in end-user revenue processed through Ezovion reflects strong adoption and engagement by healthcare providers. By launching our payment gateway, HCTI can transform this activity into direct, recurring revenue while driving margin expansion and delivering long-term shareholder value."
But that’s not all…
Most recently, the company announced:
“Healthcare Triangle Takes Bold Step toward AI-Driven Future with the Signing of a Non-Binding LOI for the Acquisition of Teyame.AI, which is on track to generate $34M in Revenue for fiscal year 2025 and would create for Healthcare Triangle a Next-Generation Global Customer Engagement Platform”
The strategic acquisition would address a critical gap in healthcare: the disconnect between advanced clinical systems and meaningful patient interaction.
By combining HCTI's “deep healthcare technology expertise with Teyame's proven AI automation customer engagement platform, an integrated ecosystem would be created where every patient touchpoint would become intelligent, personalized, and outcome-focused”.
“Based on financial information the Company has received from Teyame, the Company expects Teyame to generate approximately $34 million in incremental annual revenue and $4.2 million in incremental EBITDA for fiscal year 2025.”
The acquisition could “represent a pivotal moment in HCTI's evolution from healthcare IT provider to comprehensive digital health innovator and could significantly enhance HCTI's financial performance and shareholder value”.
Here are some of the company’s comments:
"The transaction would bring real world lived experience of Agentic Gen AI, in addition to material revenues and profitability to HCTI" added David Ayanoglou, Chief Financial Officer of HCTI"
Proven AI Innovation and Customer Engagement Meets Healthcare Expertise
Madrid-headquartered Teyame.AI has built a “sophisticated platform that seamlessly blends artificial intelligence with human expertise, currently serving banking and insurance clients while piloting breakthrough healthcare applications”.
The company's “technology stack includes advanced chatbot automation, multilingual patient engagement tools, and real-time analytics… capabilities that become exponentially more powerful when integrated with HCTI's clinical systems.”
Key highlights of Teyame's innovation include:
“Integration of Agentic Generative AI (Gen AI) into core operations.”
“Advanced AI-human collaboration models to drive efficiency.”
“Pilots of AI-powered healthcare services, such as appointment confirmations and multilingual patient engagement.”
“Evolution into a digital-first, AI-powered global CX provider.”
Building a Comprehensive Healthcare Engagement Platform
Once completed, this acquisition would create a “global, digital-first patient engagement platform that combines HCTI's healthcare technology expertise with Teyame's advanced automation capabilities”.
Key anticipated synergies include:
“Integration with QuantumNexis (HCTI Subsidiary) Products”
“Teyame's omnichannel platform will seamlessly integrate with Ziloy, QuantumNexis' advanced AI engine, and Ezovion, a comprehensive EHR/HIS solution.”
“This combination will deliver a front-end, patient engagement platform tightly connected to back-end clinical systems.”
“Enhanced Patient Engagement”:
“Expansion of Ziloy's digital mental health programs using chatbot-led, AI-driven workflows.”
“Personalized care journeys and outreach based on real-time patient data.”
“Global Market Reach”:
“Expansion into Europe, Latin America, Middle East and Asia-Pacific leveraging Teyame's multilingual, scalable platform.”
“AI-Driven Personalization”:
“Intelligent automation for treatment plans, chronic care workflows, and targeted outreach, improving patient outcomes and hospital efficiency.”
“Cross-Selling Opportunities”:
“Immediate ability to introduce Teyame's capabilities to HCTI's extensive hospital and clinic network.”
“Acquisition of High-Quality Talent”:
“Strengthening HCTI's innovation team with Teyame's domain experts in AI, CX, and automation.”
As the company further notes:
"This strategic acquisition would expand our reach into international markets and provide our customers with cutting-edge Gen AI solutions," said Sujatha Ramesh, Chief Operating Officer of HCTI. "By integrating Teyame's technology and services with HCTI's healthcare offerings, we could create a next-generation, AI-powered ecosystem for patients, providers, and healthcare organizations."
Strategic Growth Alignment
This LOI could be a critical step in HCTI's broader strategy focused on:
“AI-driven healthcare innovation.”
“Global SaaS platforms for patient engagement and care management.”
“Expansion into high-growth international markets through digital-first healthcare solutions.”
By uniting human expertise with advanced AI, HCTI is “accelerating its transformation into a global healthcare technology leader, creating measurable impact for patients, providers, and shareholders”.
HCTI could breakout higher.
Make sure to do your own due diligence.
Happy Trading!
SmallCapStocks Team
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.
DISCLAIMER:
You should read and understand this disclaimer in its entirety before joining the website or email/blog list of SmallCapStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.
The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.
The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.
Owners and operators of the Publisher have been compensated eight thousand dollars by bank wire transfer on 10/16/25 for the distribution of this advertisement about HCTI dated 10/28/25. Prior to the past year, at the time of publication, we disclosed our compensation for the distribution of advertisements about HCTI. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time.
You are receiving this report/release because you subscribed to receive it at our website or through a third-party site. All our newsletters include an "unsubscribe" link, and you can remove yourself at any time from our newsletters by clicking on that "unsubscribe" link. You can also contact us at [email protected] to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link:
By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.